You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Details for Patent: 7,423,050


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 7,423,050 protect, and when does it expire?

Patent 7,423,050 protects REYVOW and is included in one NDA.

This patent has forty patent family members in thirty countries.

Summary for Patent: 7,423,050
Title:Pyridinoylpiperidines as 5-HT.sub.1F agonists
Abstract: The present invention relates to compounds of formula I: ##STR00001## or pharmaceutically acceptable acid addition salts thereof, where; R.sup.1 is C.sub.1-C.sub.6 alkyl, substituted C.sub.1-C.sub.6 alkyl, C.sub.3-C.sub.7 cycloalkyl, substituted C.sub.3-C.sub.7 cycloalkyl, C.sub.3-C.sub.7 cycloalkyl-C.sub.1-C.sub.3 alkyl, substituted C.sub.3-C.sub.7 cycloalkyl-C.sub.1-C.sub.3 alkyl, phenyl, substituted phenyl, heterocycle, or substituted heterocycle; R.sup.2 is hydrogen, C.sub.1-C.sub.3 alkyl, C.sub.3-C.sub.6 cycloalkyl-C.sub.1-C.sub.3 alkyl, or a group of formula II ##STR00002## R.sup.3 is hydrogen or C.sub.1-C.sub.3 alkyl; R.sup.4 is hydrogen, halo, or C.sub.1-C.sub.3 alkyl; R.sup.5 is hydrogen or C.sub.1-C.sub.3 alkyl; R.sup.6 is hydrogen or C.sub.1-C.sub.6 alkyl; and n is an integer from 1 to 6 inclusively. The compounds of the present invention are useful for activating 5-HT.sub.1F receptors, inhibiting neuronal protein extravasation, and for the treatment or prevention of migraine in a mammal. The present invention also relates to a process for the synthesis of intermediates in the synthesis of compounds of Formula I.
Inventor(s): Cohen; Michael Philip (Indianapolis, IN), Kohlman; Daniel Timothy (Camby, IN), Liang; Sidney Xi (Bethany, CT), Mancuso; Vincent (Thy-le-Chateau, BE), Xu; Yao-Chang (Fishers, IN), Ying; Bai-Ping (Fishers, IN), Zacherl; DeAnna Piatt (Noblesville, IN), Zhang; Deyi (Carmel, IN), Victor; Frantz (Indianapolis, IN)
Assignee: Eli Lilly and Company (Indianapolis, IN)
Application Number:10/509,770
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation; Compound;

Drugs Protected by US Patent 7,423,050

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Eli Lilly And Co REYVOW lasmiditan succinate TABLET;ORAL 211280-001 Jan 31, 2020 RX Yes No ⤷  Try a Trial ⤷  Try a Trial Y Y ACUTE TREATMENT OF MIGRAINE ⤷  Try a Trial
Eli Lilly And Co REYVOW lasmiditan succinate TABLET;ORAL 211280-002 Jan 31, 2020 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y Y ACUTE TREATMENT OF MIGRAINE ⤷  Try a Trial
Eli Lilly And Co REYVOW lasmiditan succinate TABLET;ORAL 211280-003 Dec 18, 2020 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial Y Y ACUTE TREATMENT OF MIGRAINE ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 7,423,050

PCT Information
PCT FiledMarch 27, 2003PCT Application Number:PCT/US03/08455
PCT Publication Date:October 16, 2003PCT Publication Number: WO03/084949

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.